The Food and Drug Administration has approved Baytril 100 (enrofloxacin) Injectable, manufactured by Bayer HealthCare for control of all four major Bovine Respiratory Disease pathogens in beef and non-lactating dairy cattle at high risk of developing BRD.
With the latest approval from FDA, Baytril 100 is the only fluoroquinolone approved for treatment of BRD and control of BRD in high-risk cattle. Baytril 100 can now be used for BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non lactating dairy cattle; and, for the control of BRD in beef and non-lactating dairy heifers less than 20 months of age at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
"Producers need options available when it comes to managing the welfare and health of their cattle," said Dan Thomson, DVM, Ph.D., Beef Cattle Institute, Kansas State University. "With the approval of Baytril100 for control of BRD in high-risk cattle, there is greater flexibility for the management of BRD — whether it is a metaphylaxis or treatment scenario."